Rapid and accurate in silico solubility screening of a monoclonal antibody library

Antibodies represent essential tools in research and diagnostics and are rapidly growing in importance as therapeutics. Commonly used methods to obtain novel antibodies typically yield several candidates capable of engaging a given target. The development steps that follow, however, are usually performed with only one or few candidates since they can be resource demanding, thereby increasing the risk of failure of the overall antibody discovery program. In particular, insufficient solubility, which may lead to aggregation under typical storage conditions, often hinders the ability of a candidate antibody to be developed and manufactured. Here we show that the selection of soluble lead antibodies from an initial library screening can be greatly facilitated by a fast computational prediction of solubility that requires only the amino acid sequence as input. We quantitatively validate this approach on a panel of nine distinct monoclonal antibodies targeting nerve growth factor (NGF), for which we compare the predicted and measured solubilities finding a very close match, and we further benchmark our predictions with published experimental data on aggregation hotspots and solubility of mutational variants of one of these antibodies.

[1]  Anna Tramontano,et al.  Antibody modeling using the Prediction of ImmunoGlobulin Structure (PIGS) web server , 2014, Nature Protocols.

[2]  R. Faggioni,et al.  Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. , 2011, Journal of molecular biology.

[3]  H. Kettenberger,et al.  Developability assessment during the selection of novel therapeutic antibodies. , 2015, Journal of pharmaceutical sciences.

[4]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[5]  Hardeep S Samra,et al.  Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. , 2012, Molecular pharmaceutics.

[6]  T. Laird Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals , 2013 .

[7]  Brian Kuhlman,et al.  Structure-based design of supercharged, highly thermoresistant antibodies. , 2012, Chemistry & biology.

[8]  M. Mann,et al.  Widespread Proteome Remodeling and Aggregation in Aging C. elegans , 2017, Cell.

[9]  Feroz Jameel,et al.  Formulation and process development strategies for manufacturing biopharmaceuticals , 2010 .

[10]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[11]  Bernhardt L Trout,et al.  Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.

[12]  Apollon Papadimitriou,et al.  Structure-Based Prediction of Asparagine and Aspartate Degradation Sites in Antibody Variable Regions , 2014, PloS one.

[13]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[14]  M. Bolognesi,et al.  Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability , 2016, Scientific Reports.

[15]  Christopher J Roberts,et al.  Therapeutic protein aggregation: mechanisms, design, and control. , 2014, Trends in biotechnology.

[16]  Anna Tramontano,et al.  Superposition-free comparison and clustering of antibody binding sites: implications for the prediction of the nature of their antigen , 2017, Scientific Reports.

[17]  M. Groves,et al.  Affinity maturation of phage display antibody populations using ribosome display. , 2006, Journal of immunological methods.

[18]  S. Radford,et al.  Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo , 2016, Scientific Reports.

[19]  F. Rousseau,et al.  Prediction and Reduction of the Aggregation of Monoclonal Antibodies , 2017, Journal of molecular biology.

[20]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[21]  David A. Phoenix,et al.  Prediction of Peptide and Protein Propensity for Amyloid Formation , 2014, PloS one.

[22]  O. Leavy Therapeutic antibodies: past, present and future , 2010, Nature Reviews Immunology.

[23]  Michele Vendruscolo,et al.  The CamSol method of rational design of protein mutants with enhanced solubility. , 2015, Journal of molecular biology.

[24]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[25]  P. Tessier,et al.  Toward aggregation-resistant antibodies by design. , 2013, Trends in biotechnology.

[26]  P. Tessier,et al.  Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.

[27]  Janice M. Reichert,et al.  Antibodies to watch in 2017 , 2016, mAbs.

[28]  Michele Vendruscolo,et al.  Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. , 2004, Journal of molecular biology.

[29]  D. Atha,et al.  Mechanism of precipitation of proteins by polyethylene glycols. Analysis in terms of excluded volume. , 1981, The Journal of biological chemistry.

[30]  Jaime Prilusky,et al.  A server and database for dipole moments of proteins , 2007, Environmental health perspectives.

[31]  T. Ikegami,et al.  Effects of a reduced disulfide bond on aggregation properties of the human IgG1 CH3 domain. , 2015, Biochimica et biophysica acta.

[32]  Daniel Seeliger,et al.  Boosting antibody developability through rational sequence optimization , 2015, mAbs.

[33]  David B Volkin,et al.  Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.

[34]  P. Tessier,et al.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. , 2012, Protein engineering, design & selection : PEDS.

[35]  Li Li,et al.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development , 2016, mAbs.

[36]  Sebastian Kelm,et al.  SAbPred: a structure-based antibody prediction server , 2016, Nucleic Acids Res..

[37]  Reed J. Harris,et al.  Non-enzymatic hinge region fragmentation of antibodies in solution. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[38]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[39]  Deborah S. Goldberg,et al.  Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.

[40]  N. Warne,et al.  Application of a PEG precipitation method for solubility screening: A tool for developing high protein concentration formulations , 2013, Protein science : a publication of the Protein Society.

[41]  H.,et al.  Mechanism of Precipitation of Proteins by Polyethylene Glycols , 2001 .